Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001193125-18-217909
Filing Date
2018-07-13
Accepted
2018-07-13 16:51:14
Documents
13

Document Format Files

Seq Description Document Type Size
1 424B4 d521849d424b4.htm 424B4 2418150
2 GRAPHIC g521849g14h50.jpg GRAPHIC 144801
3 GRAPHIC g521849g25i47.jpg GRAPHIC 98910
4 GRAPHIC g521849g32e47.jpg GRAPHIC 48399
5 GRAPHIC g521849g40c11.jpg GRAPHIC 92084
6 GRAPHIC g521849g41w64.jpg GRAPHIC 89429
7 GRAPHIC g521849g48n25.jpg GRAPHIC 55355
8 GRAPHIC g521849g51q40.jpg GRAPHIC 50531
9 GRAPHIC g521849g65v09.jpg GRAPHIC 191612
10 GRAPHIC g521849g78m75.jpg GRAPHIC 86180
11 GRAPHIC g521849g81r65.jpg GRAPHIC 69059
12 GRAPHIC g521849g86o64.jpg GRAPHIC 115236
13 GRAPHIC g521849g92g41.jpg GRAPHIC 72197
  Complete submission text file 0001193125-18-217909.txt   3954617
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-226093 | Film No.: 18952996
SIC: 2834 Pharmaceutical Preparations